--- canonical_name: Humulin R alternate_names: Regular Human Insulin, Insulin Human Injection USP, Humulin R U-100, Humulin R U-500, Humulin S, Soluble Human Insulin canonical_topic: Humulin R for Health & Longevity short_topic_lc: humulin_r creation_date: 2026-0904-1151 creator_ai_fullname: Opus 5 ep_keywords: Insulin, Insulin Therapy --- # Humulin R for Health & Longevity
Evidence Review created on 09/04/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** Regular Human Insulin, Insulin Human Injection USP, Humulin R U-100, Humulin R U-500, Humulin S, Soluble Human Insulin ## Motivation Humulin R is a laboratory-made copy of the insulin the human pancreas produces, sold as an injectable solution. It was the first medicine ever manufactured using genetic engineering, and it remains one of the least expensive insulin products on the market. Because insulin governs how the body stores fuel, builds tissue and manages blood sugar, it sits at the center of both diabetes care and long-running questions about metabolism and lifespan. Human insulin dominated diabetes treatment for roughly two decades before modified versions — designed to act faster or last longer — displaced it. Those newer products became far more expensive, and a share of people who need insulin have since returned to the older formulation for reasons of cost and availability. At the same time, researchers studying aging have taken a strong interest in insulin itself, since lower lifetime insulin exposure tracks with longer life in a range of species. This review examines what the evidence shows about Humulin R: how it works, where it performs comparably to newer insulins and where it does not, the risks that come with injecting it, how it is dosed and monitored, and what is known and unknown about long-term insulin exposure. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading The items below give a high-level orientation to regular human insulin — its origin, its present clinical role, its price history, and the reason insulin exposure itself matters to a longevity-focused audience. * [#41 – Jake Kushner, M.D.: How to thrive with type 1 diabetes and how everyone can benefit from the valuable insights](https://peterattiamd.com/jakekushner/) - Peter Attia A long-form conversation on living with insulin dependence, covering insulin's discovery, its effect on cellular metabolism and growth signaling, and the cost of insulin products. * [Origins of the Crisis in Insulin Affordability and Practical Advice for Clinicians on Using Human Insulin](https://pubmed.ncbi.nlm.nih.gov/31997036/) - Luo & Gellad, 2020 Explains why insulin prices rose and gives concrete clinical guidance on switching patients from analogues back to human insulin, including dose conversion and the trade-offs involved. * [Human insulin from recombinant DNA technology](https://pubmed.ncbi.nlm.nih.gov/6337396/) - Johnson, 1983 The primary account of how Humulin was created and validated, written by the Eli Lilly research head who led the program — a source with a direct commercial interest. * [Hyperinsulinemia and Its Pivotal Role in Aging, Obesity, Type 2 Diabetes, Cardiovascular Disease and Cancer](https://pubmed.ncbi.nlm.nih.gov/34360563/) - Janssen, 2021 Frames chronically elevated insulin as an upstream driver of age-related disease, the mechanism that makes any decision about injected insulin relevant to longevity rather than only to blood sugar. * [Overlooked Dangers of Excess Fasting Insulin](https://www.lifeextension.com/magazine/2019/5/overlooked-danger-of-excess-insulin) - Sonia Whitman A consumer-facing case for measuring fasting insulin rather than only glucose, with the target range this supplement retailer uses; relevant because injected insulin adds directly to that measured burden. Direct searches of Found My Fitness, Huberman Lab, Chris Kresser and Lifespan.io returned only material on insulin resistance and the body's own insulin. None of those platforms discusses regular human insulin or Humulin R as a therapy, so no item from them is listed. Five qualifying sources were found, so the list is complete and has not been padded. ## Grokipedia [Regular insulin](https://grokipedia.com/page/Regular_insulin) Grokipedia's dedicated entry for this compound is titled "Regular insulin"; it covers the recombinant manufacture, both marketed strengths, the mixed formulations and the brand naming across manufacturers. ## Examine No Examine.com article exists for Humulin R; a direct site search returned no results. Examine.com covers dietary supplements and nutrition, not prescription medications such as injectable insulin. ## ConsumerLab No ConsumerLab article exists for Humulin R; a direct site search returned no results. ConsumerLab tests dietary supplements and foods, not prescription medications such as injectable insulin. ## Systematic Reviews The following systematic reviews and meta-analyses cover regular human insulin's effectiveness against modern analogues and the principal harms of injected insulin, and they pool head-to-head trials funded largely by the manufacturers that sell both the older human insulins and the newer analogues — a conflict of interest noted again in the Conclusion. * [(Ultra-)short-acting insulin analogues for adults with type 1 diabetes mellitus on multiple daily injections: a network meta-analysis](https://pubmed.ncbi.nlm.nih.gov/42318853/) - Guo et al., 2026 Fifteen trials, 6,335 adults with type 1 diabetes: this 2026 Cochrane update ranks the analogues against regular human insulin as the network's reference treatment. * [Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus](https://pubmed.ncbi.nlm.nih.gov/30556900/) - Fullerton et al., 2018 Ten trials, 2,751 adults: no clear benefit of analogues over regular human insulin on average blood sugar, deaths or severe episodes. * [Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/30622653/) - Melo et al., 2019 Twenty-two trials, 6,235 patients with type 1 diabetes: analogues reduced total, nighttime and severe low-blood-sugar episodes and lowered post-meal glucose. * [Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/38215209/) - Mader et al., 2024 Thirty-seven studies: injection-site lumps were associated with far more unexplained low blood sugar, worse control and higher daily insulin use. * [Clinical use of U-500 regular insulin: review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/22538155/) - Reutrakul et al., 2012 Pooled 365 patients: the concentrated U-500 formulation cut average blood sugar substantially in severe insulin resistance, at the cost of weight gain. ## Mechanism of Action Humulin R is recombinant human insulin, identical in amino acid sequence to the hormone the pancreas secretes. Injected under the skin, it forms zinc-stabilized hexamers (six-molecule clusters) that must dissociate before absorption, which is why onset takes roughly 30 minutes, effect peaks at 2–4 hours and action persists 6–8 hours. Once in circulation it binds the insulin receptor, a tyrosine kinase (an enzyme that adds phosphate groups to proteins). Receptor activation recruits insulin receptor substrate proteins and triggers the PI3K/Akt pathway (a signaling cascade governing fuel storage), which moves GLUT4 (the main glucose transporter in muscle and fat) to the cell surface, suppresses hepatic glucose output, drives potassium into cells and inhibits fat breakdown. A second branch, the MAPK pathway (mitogen-activated protein kinase, which regulates cell growth and division), mediates growth-promoting rather than metabolic effects. Circulating insulin has a half-life of about 4–6 minutes; the subcutaneous depot, not clearance, determines duration. Clearance occurs mainly in liver and kidney via receptor-mediated uptake and insulin-degrading enzyme; cytochrome P450 enzymes (the liver's main drug-metabolizing system) are not involved, so classical metabolic drug interactions are absent. Selectivity is imperfect: at high concentrations insulin also engages the IGF-1 receptor (insulin-like growth factor 1, a growth signal). Whether that cross-reactivity is clinically meaningful is disputed — one view holds it drives tissue proliferation, the other that human insulin's low IGF-1 receptor affinity makes it negligible. ## Historical Context & Evolution Insulin entered clinical use in 1922 as an extract of animal pancreas, and animal-sourced preparations remained the standard for six decades. Rising diabetes prevalence raised the prospect that pancreas supply would not keep pace, and animal insulins carried impurities that provoked immune reactions. Genentech scientists synthesized the human insulin gene in bacteria in 1978; Eli Lilly scaled the process and the Food and Drug Administration approved Humulin in October 1982, making it the first medicine of any kind produced by genetic engineering ([Johnson, 1983](https://pubmed.ncbi.nlm.nih.gov/6337396/)). Its original purpose was replacement, not optimization: supplying the hormone that people with diabetes cannot make in sufficient quantity. Interest beyond that grew along two lines. Strength athletes began using it off-label for its growth-promoting branch, and aging researchers noted that reduced insulin signaling extends lifespan in worms, flies and mice, which made insulin exposure itself a variable worth measuring. From the mid-1990s, engineered analogues with faster or flatter profiles displaced human insulin in wealthy markets. Trials comparing the two found small differences in average blood sugar and mixed findings on low-blood-sugar episodes; the largest reviews concluded the [analogue advantage in type 2 diabetes was not clearly demonstrated](https://pubmed.ncbi.nlm.nih.gov/30556900/). That reading is not settled — later [analyses in type 1 diabetes](https://pubmed.ncbi.nlm.nih.gov/30622653/) report fewer low-blood-sugar episodes with analogues, while the low-cost profile and long safety record of human insulin have kept it in guidelines and returned it to use as insulin prices rose. ## Expected Benefits ### High 🟩 🟩 🟩 #### Blood-Sugar Control Comparable to Rapid-Acting Analogues in Type 2 Diabetes Across randomized trials in adults with type 2 diabetes, regular human insulin and rapid-acting analogues produce essentially the same glycated hemoglobin (HbA1c — a blood test reflecting average blood sugar over roughly three months). A [Cochrane review of ten trials](https://pubmed.ncbi.nlm.nih.gov/30556900/) found a mean difference of −0.03%, and a [health-plan switch of 14,635 members](https://pubmed.ncbi.nlm.nih.gov/30694321/) raised population HbA1c by only 0.14%. Certainty was rated low because none of the trials were blinded and reporting was inconsistent. For someone dosing carefully and tracking glucose, the practical gap is small. **Magnitude:** Mean HbA1c difference −0.03% (95% confidence interval — the range within which the true effect most likely sits — −0.16 to 0.09) versus rapid-acting analogues in type 2 diabetes; a real-world switch of an entire health plan raised mean HbA1c by 0.14%. #### Reduction of Small-Vessel Complications With Intensive Replacement In people who cannot make insulin, replacement is not optional, and tightening it changes hard outcomes. The [Diabetes Control and Complications Trial](https://pubmed.ncbi.nlm.nih.gov/8366922/) used regular and intermediate-acting human insulin and cut new retinopathy (damage to the light-sensing layer of the eye) by 76% and clinical neuropathy (nerve damage) by 60%. The [UK Prospective Diabetes Study](https://pubmed.ncbi.nlm.nih.gov/9742976/) found a 25% reduction in microvascular (small-vessel) endpoints in type 2 diabetes. Both trials predate analogues; the benefit attaches to glucose control achieved with this insulin. **Magnitude:** 76% relative reduction in retinopathy onset (95% confidence interval 62–85%) and 60% in clinical neuropathy over a mean 6.5 years in type 1 diabetes; 25% relative reduction in microvascular endpoints (95% confidence interval 7–40%) over 10 years in type 2 diabetes. #### Rapid Lowering of Dangerously High Blood Potassium Intravenous regular human insulin, given with glucose, is the fastest reliable way to move potassium from blood into cells and is standard emergency treatment for hyperkalemia (dangerously high blood potassium, which can trigger fatal heart rhythms). A [systematic review of eleven studies](https://pubmed.ncbi.nlm.nih.gov/27148740/) found ten units intravenously lowers serum potassium within an hour, with no clear advantage for larger doses. Analogues are not used here; this is an indication where the regular formulation is the reference agent. **Magnitude:** Mean serum potassium fall of 0.78 mmol/L (standard deviation — the typical spread of results around the average — 0.25) within 60 minutes after 10 units intravenously; 20 units infused over an hour gave a statistically indistinguishable 0.79 mmol/L. ### Medium 🟩 🟩 #### Resolution of Diabetic Ketoacidosis Equivalent to Analogue Insulin Diabetic ketoacidosis (a life-threatening state in which lack of insulin drives the blood acidic) is treated with a continuous intravenous insulin infusion. A [randomized trial in 68 adults](https://pubmed.ncbi.nlm.nih.gov/19366972/) found no difference between intravenous regular human insulin and intravenous glulisine in time to resolution or total insulin needed. The advantage disappears after the acute phase: transition to intermediate-acting plus regular insulin produced more low-blood-sugar episodes than a glargine-based regimen. Evidence rests on this single controlled comparison. **Magnitude:** No significant difference in mean duration of intravenous treatment or in insulin required until ketoacidosis resolved; after transition, hypoglycemia (low blood sugar) occurred in 41% on intermediate-acting plus regular insulin versus 15% on glargine plus glulisine. #### Effective Glucose Control in Severe Insulin Resistance With the U-500 Concentrate Humulin R U-500 (500 units per milliliter, five times standard strength) is the main option when daily requirements exceed roughly 200 units, where injection volume otherwise becomes impractical. A [meta-analysis of 365 patients](https://pubmed.ncbi.nlm.nih.gov/22538155/) reported a 1.59% HbA1c reduction with multiple daily injections. The [VIVID randomized trial](https://pubmed.ncbi.nlm.nih.gov/31865633/) in 420 adults, funded by the product's manufacturer, confirmed reductions by both injection and pump delivery. Most supporting data are uncontrolled case series, and weight gain accompanied the improvement. **Magnitude:** HbA1c fell 1.59% with multiple daily injections and 1.64% with pump delivery in pooled series; in the VIVID trial HbA1c fell 1.27% with a pump versus 0.85% with injections over 24 weeks. ### Low 🟩 #### Memory Benefit From Intranasal Delivery ⚠️ Conflicted Regular human insulin sprayed into the nose reaches the brain without raising blood insulin much. Two [pilot](https://pubmed.ncbi.nlm.nih.gov/21911655/) [trials](https://pubmed.ncbi.nlm.nih.gov/28372335/) improved delayed memory in mild cognitive impairment; a [larger trial](https://pubmed.ncbi.nlm.nih.gov/32568367/) with a different device found none. Net reading: promising but unconfirmed and device-dependent. **Magnitude:** Delayed story recall improved significantly over four months at 20 units daily in the first pilot trial and at 40 units daily in the second; the larger multicenter trial reported no significant difference on its primary cognitive composite. ### Speculative 🟨 #### Anabolic Support for Lean Mass in Non-Diabetic Users Strength athletes use insulin to drive amino acids and glucose into muscle. No controlled trial has tested lean-mass outcomes in healthy adults; the basis is mechanistic plus case reports of severe hypoglycemia. ## Benefit-Modifying Factors * **Residual pancreatic output:** Measurable C-peptide (a fragment released when the pancreas makes its own insulin) predicts smaller dose requirements, smoother control and a larger relative gain from any given injected dose. * **Baseline HbA1c and fasting insulin:** The higher the starting HbA1c, the larger the absolute reduction achievable. A high fasting insulin signals resistance, which shifts the useful formulation toward the concentrated U-500 product. * **Genetic variants:** TCF7L2 variants (a transcription factor governing insulin secretion) predict poorer response to oral agents and earlier insulin need. HNF1A and HNF4A variants (causing maturity-onset diabetes of the young) respond better to sulfonylureas (drugs prompting the pancreas to release insulin) than to insulin. * **Sex-based differences:** Women require dose adjustment across the menstrual cycle, since progesterone in the luteal phase reduces insulin sensitivity. In pregnancy, human insulin does not cross the placenta and has the longest safety record. * **Pre-existing conditions:** Kidney impairment prolongs insulin action and lowers requirements; liver disease reduces the glucose reserve that protects against overshoot. Untreated cortisol excess or acromegaly (growth hormone excess from a pituitary tumor) blunts response until the disorder is addressed. * **Age:** Older adults gain less from tight targets because the low-blood-sugar penalty rises steeply with age, while the small-vessel benefits take a decade to accrue and may exceed remaining life expectancy. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 #### Hypoglycemia, Including Severe Episodes Every insulin lowers glucose whether or not glucose is available, so low blood sugar is the defining hazard. In the [UK Prospective Diabetes Study](https://pubmed.ncbi.nlm.nih.gov/9742976/) major episodes occurred in 1.8% of insulin-treated participants per year, the highest of any arm. A [meta-analysis of 22 trials](https://pubmed.ncbi.nlm.nih.gov/30622653/) in type 1 diabetes found regular human insulin caused more severe and more nighttime episodes than analogues, plausibly because its 6–8 hour tail outlasts the meal. Non-prescribed use carries the same hazard without medical supervision, and [coma has been reported](https://pubmed.ncbi.nlm.nih.gov/30527564/). **Magnitude:** Severe hypoglycemia relative risk (the event rate in one group divided by the rate in the other) 0.68 (95% confidence interval 0.60–0.77) favoring analogues, meaning roughly a 47% higher rate with regular human insulin; nighttime episodes relative risk 0.55 (0.40–0.76); major episodes 1.8 per 100 patient-years on insulin in type 2 diabetes. #### Weight Gain Insulin promotes fat storage and reduces glucose loss in urine, so restoring control adds weight. Over ten years in the [UK Prospective Diabetes Study](https://pubmed.ncbi.nlm.nih.gov/9742976/) insulin-assigned participants gained 4.0 kg, more than any oral comparator. [Pooled U-500 series](https://pubmed.ncbi.nlm.nih.gov/22538155/) show 4.38 kg with multiple daily injections. For a longevity-oriented adult the gain is mostly fat mass and directly opposes the metabolic goals that motivate careful glucose management. **Magnitude:** Mean gain 4.0 kg over 10 years versus 1.7–2.6 kg with sulfonylureas in type 2 diabetes; 4.38 kg with the U-500 concentrate given by multiple daily injections. #### Lipohypertrophy at Injection Sites Repeated injection into the same area produces lipohypertrophy (rubbery fatty lumps under the skin), which absorbs insulin erratically. A [meta-analysis of 37 studies](https://pubmed.ncbi.nlm.nih.gov/38215209/) found affected patients had far higher odds of unexplained low blood sugar, worse average control and higher daily doses. A rarer variant, [insulin-derived amyloidosis](https://pubmed.ncbi.nlm.nih.gov/31867887/) (protein deposits at the site), can occur without a palpable lump and blocks absorption more severely. Rotation prevents both; the lesion is reversible if the area is rested. **Magnitude:** Odds ratio (how much more likely the event is in one group than the other) 6.98 (95% confidence interval 3.30–14.77) for unexplained hypoglycemia, HbA1c 0.55% higher (0.23–0.87) and 7.68 more units per day (5.31–10.06) in patients with lipohypertrophy versus without. ### Medium 🟥 🟥 #### Hypokalemia Insulin drives potassium into cells independently of glucose, so overshoot is a genuine hazard whenever it is given intravenously or in large doses. [Prospective emergency-department data](https://pubmed.ncbi.nlm.nih.gov/21316179/) found 5.6% of patients presenting in diabetic ketoacidosis were already potassium-depleted before any insulin, which is why guidelines require a potassium measurement first. Severe hypokalemia (low blood potassium) can provoke fatal arrhythmias (abnormal heart rhythms). The risk is confined to acute high-dose settings, not routine subcutaneous dosing. **Magnitude:** 5.6% (95% confidence interval 1.2–15.4%) of patients arriving in diabetic ketoacidosis had serum potassium below 3.3 mmol/L before any insulin was given; 10 units intravenously lowers serum potassium by about 0.78 mmol/L within an hour. #### Dementia Risk After Severe Hypoglycemic Episodes Severe low-blood-sugar episodes appear to leave lasting cognitive damage. A [27-year cohort of 16,667 older adults](https://pubmed.ncbi.nlm.nih.gov/19366776/) with type 2 diabetes found a graded increase in dementia diagnoses with the number of episodes requiring hospital care. The association is observational and could partly reflect early dementia causing dosing errors, but the dose-response pattern and long follow-up make reverse causation an incomplete explanation. For an audience prioritizing healthspan this is the most consequential downstream risk. **Magnitude:** Hazard ratio (the relative rate of an event over time) 1.26 (95% confidence interval 1.10–1.49) after one episode, 1.80 after two and 1.94 after three or more; attributable risk (the share of cases traceable to the exposure) 2.39% per year. ### Low 🟥 #### Cancer Incidence ⚠️ Conflicted Insulin signals through growth pathways, prompting concern that long-term therapy promotes tumors. [ORIGIN](https://pubmed.ncbi.nlm.nih.gov/22686416/), a randomized trial of basal insulin, and a [cohort comparing human insulin with an analogue](https://pubmed.ncbi.nlm.nih.gov/23877991/) found no excess, while [earlier registry analyses](https://pubmed.ncbi.nlm.nih.gov/19565214/) suggested a signal; neither tested this product directly. Net reading: no demonstrated excess. **Magnitude:** Cancer hazard ratio 1.00 (95% confidence interval 0.88–1.13) with basal insulin versus standard care over 6.2 years; 1.12 (0.95–1.32) for an analogue versus human intermediate-acting insulin over about one year of follow-up. #### Insulin Allergy and Local Hypersensitivity Reactions Recombinant human insulin markedly reduced but did not eliminate allergic reactions, which range from itching and wheals at the site to rare systemic responses. Excipients such as zinc and metacresol are sometimes the true trigger. The [available literature](https://pubmed.ncbi.nlm.nih.gov/17216593/) is case series and reviews, not controlled trials. **Magnitude:** Not quantified in available studies. No controlled trial has measured incidence with recombinant human insulin, so the evidence is limited to case reports and uncontrolled series. #### Insulin Edema Starting or intensifying insulin can cause sudden fluid retention through renal sodium reabsorption, producing swelling of the legs and occasionally the face. It appears within days to weeks and usually resolves without treatment. The [evidence base](https://pubmed.ncbi.nlm.nih.gov/36180933/) is individual case reports. **Magnitude:** Not quantified in available studies. Only case reports exist, so no incidence rate or effect size has been measured. ### Speculative 🟨 #### Accelerated Aging From Sustained Exogenous Hyperinsulinemia Reduced insulin signaling extends lifespan in model organisms, and [a review](https://pubmed.ncbi.nlm.nih.gov/34360563/) places hyperinsulinemia (persistently high blood insulin) upstream of age-related disease. No human study tests whether injected insulin shortens healthspan; the basis is mechanistic only. ## Risk-Modifying Factors * **Genetic variants:** Variants in the insulin-degrading enzyme gene IDE (the enzyme that breaks insulin down) alter clearance and can prolong action. Insulin receptor gene defects cause extreme resistance requiring the concentrated formulation. * **Baseline biomarkers:** A low HbA1c before starting, low C-peptide and a reduced estimated glomerular filtration rate (a measure of kidney filtering capacity) each raise low-blood-sugar risk; baseline potassium below 3.5 mmol/L forbids intravenous use. * **Sex-based differences:** Women report severe low-blood-sugar episodes more often at equivalent control, and the luteal phase of the menstrual cycle shifts requirements upward, so fixed dosing produces predictable overshoot in the follicular phase. * **Pre-existing conditions:** Chronic kidney disease, adrenal insufficiency, liver disease and gastroparesis (delayed stomach emptying) all extend or mistime insulin action. Coronary disease turns a low-blood-sugar episode into a cardiac event. * **Age:** Older adults lose the adrenaline warning symptoms of low blood sugar, live alone more often, and carry the dementia risk described above, so the same dose carries substantially more consequence past roughly 65. ## Key Interactions & Contraindications * **Beta-blockers (propranolol, metoprolol, atenolol — drugs that slow the heart and lower blood pressure):** Caution. They mask the adrenaline warning signs of low blood sugar and blunt recovery. Cardioselective agents and more frequent glucose monitoring are the usual mitigations. * **Corticosteroids (prednisone, dexamethasone, methylprednisolone — drugs that suppress inflammation and immune activity):** Monitor closely. They raise glucose and insulin requirements sharply, often by 20–50%, and requirements fall just as fast on taper — a common cause of severe overshoot. * **SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin — drugs that make the kidney excrete glucose):** Caution. Additive glucose lowering plus a risk of ketoacidosis at near-normal glucose. Insulin is typically reduced by roughly 20%, with ketone monitoring. * **GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide — drugs mimicking a gut hormone that slows stomach emptying):** Caution. Strongly additive. Mealtime insulin is typically reduced 20% at initiation, with further reduction as appetite falls. * **Alcohol (over-the-counter and dietary):** Caution. It blocks the liver's glucose release for up to 12 hours, producing delayed nighttime lows. Carbohydrate alongside intake and an overnight glucose check are the standard mitigations. * **Over-the-counter medications:** Caution. High-dose aspirin and salicylates potentiate glucose lowering; oral decongestants (pseudoephedrine, phenylephrine) and high-dose niacin raise glucose and requirements. Dose adjustment and monitoring are preferred to avoidance. * **Supplements with additive glucose-lowering effects:** Caution. Berberine, alpha-lipoic acid, chromium, cinnamon, bitter melon, fenugreek and gymnema all lower glucose independently. Insulin is reduced proportionally, and their introduction is separated from any dose change. * **Thiazolidinediones (pioglitazone, rosiglitazone — drugs that improve the body's sensitivity to insulin):** Caution, and absolute contraindication in symptomatic heart failure. Combined with insulin they cause additive fluid retention and can precipitate decompensation. Weekly weight and ankle-swelling checks apply. * **Other interventions:** Caution. Prolonged fasting, ketogenic diets, endurance exercise and bariatric surgery all cut insulin requirements substantially and abruptly; each warrants a pre-emptive dose reduction rather than reactive correction. **Populations who should avoid Humulin R:** * Anyone during an episode of hypoglycemia (blood glucose below 70 mg/dL) — absolute contraindication until corrected * Anyone with documented hypersensitivity to insulin human or to the excipients metacresol or glycerin — absolute contraindication * People with hypokalemia (serum potassium below 3.3 mmol/L) before intravenous administration — absolute contraindication until repleted * Non-diabetic adults seeking body-composition change — no approved indication and a documented risk of coma * People with hypoglycemia unawareness who have no continuous glucose monitoring and no capable household support * People prescribed the U-500 concentrate who cannot obtain U-500-specific syringes or the dedicated pen device * People with Child-Pugh Class C liver disease or an estimated glomerular filtration rate below 30 mL/min/1.73 m² without specialist dose supervision ## Risk Mitigation Strategies * **Thirty-minute pre-meal injection lag:** Regular insulin peaks at 2–4 hours, so protocols place the dose 30 minutes ahead of the meal. The lag mitigates both the post-meal spike and the delayed low blood sugar that follow table-side dosing. * **Low starting dose with slow titration:** Protocols typically begin at 0.2 units/kg/day total and increase by 2 units or 10% no more than every three days. Slow escalation mitigates the severe low-blood-sugar episodes that drive dementia risk. * **Mapped injection-site rotation:** Practitioners use a defined grid within each region, with at least 1 cm between sites and weekly region changes. This mitigates lipohypertrophy and the erratic absorption that causes unexplained lows. * **Four-hour minimum between correction doses:** Because action persists 6–8 hours, a correction given at three hours adds to insulin still working. Spacing corrections mitigates dose stacking, a leading cause of severe overshoot. * **Fast carbohydrate kept within reach:** Protocols specify 15–20 g of glucose tablets or juice with a retest after 15 minutes. Immediate availability mitigates severe hypoglycemia, the intervention's defining hazard, by making it self-manageable. * **Concentration verification for every U-500 dose:** Only U-500 syringes or the dedicated pen are used, with the dose stated in units rather than volume. This mitigates the fivefold concentration error behind life-threatening overdoses. * **Pre-exercise dose reduction:** The pre-exercise mealtime dose is typically cut 25–50% for sessions over 45 minutes, with overnight glucose rechecked. This mitigates the lows that exercise-enhanced sensitivity can produce up to 24 hours later. * **Potassium measurement before intravenous use:** A level below 3.3 mmol/L is corrected before insulin is given, because insulin drives potassium into cells and can precipitate fatal arrhythmias in an already depleted person. ## Therapeutic Protocol * **Standard basal-bolus regimen:** Regular insulin before each meal with intermediate-acting NPH (neutral protamine Hagedorn, a longer-acting human insulin) at bedtime. Roughly half the total daily dose is basal, half divided across meals. * **Alternative twice-daily premixed regimen:** A fixed 70/30 intermediate-to-regular mixture before breakfast and dinner, two-thirds in the morning. Fewer injections, less flexibility, and a stricter requirement for fixed meal times. * **Competing approach — analogue basal-bolus:** Long-acting glargine or degludec with rapid-acting lispro or aspart. Neither approach is the default: analogues offer timing flexibility, human insulin offers cost and a longer safety record. * **Who popularized each approach:** The human-insulin protocols in current use follow the switching guidance of [Luo & Gellad at the University of Pittsburgh](https://pubmed.ncbi.nlm.nih.gov/31997036/); the U-500 pump protocol was developed at Mountain Diabetes and formalized in the [VIVID trial](https://pubmed.ncbi.nlm.nih.gov/31865633/). * **Best time of day:** Mealtime doses go in 30 minutes before eating. The evening intermediate dose is placed at bedtime rather than dinner so its peak falls near dawn rather than at 2 a.m. * **Half-life and duration:** Circulating half-life is 4–6 minutes, but the subcutaneous depot gives 30-minute onset, a 2–4 hour peak and 6–8 hour duration. Duration, not half-life, dictates the dosing interval. * **Split rather than single dosing:** Mealtime insulin is divided across meals in proportion to carbohydrate; a single large dose cannot match the pattern. Doses above 50 units at one site absorb unpredictably and should be split anatomically. * **Genetic considerations:** Confirmed HNF1A or HNF4A maturity-onset diabetes of the young responds better to sulfonylureas, so genotyping precedes any commitment to insulin. Insulin receptor mutations require the U-500 concentrate from the outset. * **Sex-based dosing differences:** Requirements typically rise 10–20% in the luteal phase of the menstrual cycle and fall at menstruation. In pregnancy, human insulin remains the reference choice and requirements roughly double by the third trimester. * **Age-related adjustment:** Past 65, start at 0.1–0.2 units/kg/day and accept a higher HbA1c target of 7.0–7.5%, because the low-blood-sugar penalty outweighs a small-vessel benefit that takes a decade to appear. * **Baseline biomarkers guiding dose:** C-peptide, HbA1c and weight set the starting dose; fasting insulin above roughly 25 µIU/mL with requirements over 200 units per day moves the choice to the U-500 concentrate. * **Pre-existing conditions:** The starting dose is reduced by 25% when the estimated glomerular filtration rate falls below 60 mL/min/1.73 m² and by half below 30, since impaired clearance prolongs action and compounds overshoot. The treatment algorithms that place analogue insulin ahead of human insulin come from the American Diabetes Association and the European Association for the Study of Diabetes; both organizations receive substantial corporate sponsorship from the manufacturers whose analogue products those algorithms favor, and their member endocrinologists derive practice revenue from the intensified regimens they endorse. The counter-pressure is also financial: insurers and national health systems pay roughly ten times more for analogues than for Humulin R, giving them a systematic incentive to favor human insulin in formulary design and to fund the comparative-effectiveness research that supports it. Both incentives bear on the interpretation of either side's literature. ## Discontinuation & Cycling * **Lifelong in type 1 diabetes:** Where the pancreas produces no insulin, this is permanent replacement. Stopping for more than a few hours precipitates diabetic ketoacidosis, which is a medical emergency rather than a withdrawal syndrome. * **Often reversible in type 2 diabetes:** Substantial weight loss, bariatric surgery or the addition of a GLP-1 receptor agonist can restore enough endogenous function that insulin becomes unnecessary. Discontinuation is planned, not spontaneous. * **No withdrawal effects in the pharmacological sense:** Insulin produces no dependence or rebound at the receptor. What follows a stop is simply the return of the underlying glucose disorder, at the rate the disorder dictates. * **Tapering protocol:** The total daily dose is reduced by 10–20% per week while glucose remains in range, with mealtime doses removed before the basal dose. Abrupt cessation risks ketoacidosis even in type 2 diabetes. * **No rationale for cycling:** No tolerance develops to insulin at the receptor, so there is nothing for a break to restore. Rising dose requirements reflect weight gain, lipohypertrophy or disease progression, each of which has its own remedy. ## Sourcing and Quality * **Regulatory status of the product itself:** Humulin R U-100 is a manufactured biological medicine held to pharmacopeial identity and potency standards, so third-party purity testing — relevant for supplements — does not apply. Only one manufacturer produces it. * **Two strengths, two supply routes:** U-100 is sold without a prescription in most United States pharmacies; U-500 requires a prescription. Confusing the two is the single most consequential sourcing error and has caused fatal overdoses. * **Price and access programs:** Eli Lilly's Insulin Value Program caps out-of-pocket cost near $35 per month, and the unbranded ReliOn Novolin R equivalent sells for roughly $25 per vial. Neither requires insurance. * **Storage requirements:** Unopened vials are stored refrigerated at 2–8 °C. An in-use vial is good for 31 days at room temperature below 30 °C. Frozen or heat-exposed insulin loses potency silently and is discarded. * **Avoid grey-market and online resale:** Insulin bought outside a licensed pharmacy carries real counterfeit and cold-chain risk, and there is no way to verify potency from the vial. Price savings over the manufacturer program are negligible. * **Device compatibility:** U-500 must be drawn with U-500-specific syringes or given via the dedicated KwikPen. Using a U-100 syringe for U-500 delivers five times the intended dose. ## Practical Considerations * **Time to effect:** Glucose falls within 30–60 minutes of a dose. Fasting glucose stabilizes over one to two weeks of titration, while HbA1c takes about three months to reflect the new steady state. * **Common pitfall — injecting at the table:** The 30-minute pre-meal lag is the single behaviour that distinguishes this insulin from analogues. Skipping it produces a post-meal spike followed by a late low, and is the most frequent dosing error. * **Common pitfall — dose stacking:** Because action persists 6–8 hours, correcting a high reading before the previous dose has finished compounds two doses. Waiting four hours between corrections prevents most severe episodes. * **Common pitfall — unrotated sites:** Convenience drives repeated injection into one favoured spot, producing lipohypertrophy and erratic absorption that is then misread as insulin resistance and answered with a dose increase. * **Regulatory status:** Approved by the Food and Drug Administration since 1982 and available without a prescription in most states, but the sole approved indication is glycemic control in diabetes. Use for body composition is off-label and unstudied. * **Cost and accessibility:** Among the cheapest chronic medications available, at roughly $25–35 per vial versus $300 or more for analogues at list price. Neither cost nor availability is a practical barrier in the United States. ## Interaction with Foundational Habits * **Sleep:** Bidirectional and mostly adverse. Nighttime low blood sugar fragments sleep and produces morning headaches; conversely, a single night of restricted sleep raises next-day insulin requirements by measurable amounts through cortisol and sympathetic activation. Placing the intermediate-acting dose at bedtime rather than dinner moves its peak away from the 2 a.m. nadir. * **Nutrition:** Directly coupled. Dose follows carbohydrate quantity, so a consistent carbohydrate pattern is more valuable here than with analogues, whose flexibility tolerates variation. The 30-minute lag suits slower-digesting, higher-fibre and higher-protein meals well and matches refined carbohydrate poorly. Alcohol blocks hepatic glucose release for up to 12 hours. * **Exercise:** Strongly potentiating. Muscle contraction moves GLUT4 to the cell surface independently of insulin, so the two effects add. Aerobic sessions over 45 minutes warrant a 25–50% pre-meal dose cut, and enhanced sensitivity persists up to 24 hours. Injection into a limb about to be worked absorbs faster, since exercise raises blood flow. * **Stress management:** Indirect and blunting. Cortisol and adrenaline raise liver glucose output and induce transient insulin resistance, so acute stress and illness raise requirements — often by 20% or more — while resolution of a stressor lowers them just as fast. Breath work and consistent sleep reduce the swing rather than the average. ## Monitoring Protocol & Defining Success Baseline work before any insulin is started establishes both safety limits and the yardstick for success: a full metabolic panel including potassium and creatinine, glycated hemoglobin, fasting insulin and C-peptide to document how much insulin the pancreas still makes, a lipid panel, and body weight with waist circumference. Kidney function matters because insulin clearance falls as filtration declines, which prolongs its action. Ongoing monitoring follows a fixed cadence: capillary or continuous glucose review weekly during titration, glycated hemoglobin at three months and then every three to six months, potassium and creatinine at three months and annually thereafter, weight monthly, and a physical inspection of every injection site at each visit. Any unexplained low reading triggers an earlier site check rather than a dose change. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | HbA1c | 6.0–6.5% in adults under 65; 7.0–7.5% past 65 | Average blood sugar over ~3 months | HbA1c = glycated hemoglobin. Conventional target is under 7.0% for all adults; the functional split reflects the steep low-blood-sugar penalty with age. No fasting needed | | Fasting insulin | Under 5 µIU/mL endogenously; not interpretable once injecting | Quantifies the insulin burden that longevity practitioners aim to minimize | Conventional laboratory ranges run to roughly 25 µIU/mL, five times the functional ceiling. Injected insulin is measured by most assays, so the value loses meaning after starting. Draw at baseline, fasting 10–12 h | | C-peptide (fasting) | Above 0.6 ng/mL indicates useful residual output | Shows how much insulin the pancreas still makes | C-peptide = connecting peptide, released alongside the body's own insulin but not present in injected insulin. Conventional fasting range is 0.8–3.9 ng/mL, so the functional floor sits below it. Pair with a simultaneous glucose | | Time in range (continuous glucose monitoring) | Above 70% of readings between 70–180 mg/dL | The most actionable day-to-day measure of control | CGM = continuous glucose monitoring. Also track time below 70 mg/dL, which should stay under 4%. Conventional care often omits this entirely | | Serum potassium | 4.0–4.5 mmol/L | Insulin drives potassium into cells; depletion causes arrhythmias | Conventional range is 3.5–5.0 mmol/L; the tighter functional floor gives margin. Mandatory before any intravenous dose. Avoid a tight tourniquet, which falsely raises the value | | eGFR | Above 80 mL/min/1.73 m² | Falling filtration prolongs insulin action and raises overshoot risk | eGFR = estimated glomerular filtration rate, a measure of kidney filtering capacity. Conventional threshold for concern is 60. Pair with urine albumin-to-creatinine ratio | | Body weight and waist circumference | Waist under 94 cm (men) / 80 cm (women); weight stable within 2 kg | Detects the fat gain that insulin predictably causes | No established biomarker target exists for the insulin-attributable fraction; track change from the individual's own pre-treatment baseline. Measure fasting, same time of day | | Fasting lipid panel | Triglycerides under 100 mg/dL; HDL above 50 mg/dL | Insulin suppresses fat breakdown and shifts the lipid pattern | HDL = high-density lipoprotein. Conventional triglyceride cut-off is 150 mg/dL. Requires a 12-hour fast | Qualitative markers matter as much as the panel, because they surface problems the labs average away: * Frequency and severity of low-blood-sugar symptoms, and whether warning signs are still felt at all * Sleep continuity and the presence of night sweats or morning headaches, which suggest nighttime lows * Energy stability across the afternoon, when the 6–8 hour tail of a lunchtime dose is fading * Cognitive clarity and short-term recall, given the association between severe episodes and later decline * Appearance and texture of injection sites — visible lumps, dimpling or reduced sensation ## Emerging Research * **Portal delivery of concentrated regular insulin:** [NCT07341373](https://clinicaltrials.gov/study/NCT07341373) is a recruiting Phase 1 clamp study in 25 adults with type 1 diabetes, testing intraperitoneal U-500 human insulin. Delivering insulin to the liver first would mimic natural secretion and could reduce the peripheral insulin excess that concerns longevity-minded users. * **Combination metabolic therapy for cognition:** [NCT06072963](https://clinicaltrials.gov/study/NCT06072963), a Phase 2 trial recruiting 80 adults with mild cognitive impairment and metabolic syndrome, pairs intranasal insulin with semaglutide and measures cognition, cerebral blood flow and brain glucose uptake. A positive result would strengthen the non-diabetic case for this molecule. * **Insulin alongside anti-amyloid therapy:** [NCT07756294](https://clinicaltrials.gov/study/NCT07756294), a Phase 2 study of 30 participants opening September 2026, tests intranasal insulin against empagliflozin, each as an add-on to amyloid-clearing drugs in Alzheimer's disease, with treatment-related serious adverse events as the primary endpoint. * **Evidence that could weaken the case:** the [network meta-analysis in type 1 diabetes](https://pubmed.ncbi.nlm.nih.gov/42318853/) of Guo et al., 2026 ranks ultra-rapid and rapid analogues against each other, and the [trial-sequential analysis in children](https://pubmed.ncbi.nlm.nih.gov/42134835/) of Petersen et al., 2026 found the comparison underpowered; larger head-to-head trials could still show a clear analogue advantage. * **Unanswered long-term question:** Fullerton et al., 2018 and Guo et al., 2026 both note that [no trial was designed](https://pubmed.ncbi.nlm.nih.gov/30556900/) to measure death, heart attack or kidney failure with either insulin type. Choosing between them therefore rests on short-term glucose and low-blood-sugar data rather than lifespan outcomes. * **Biosimilar competition:** a [Phase 1 comparison](https://clinicaltrials.gov/study/NCT05413863) of Biocon's concentrated regular insulin against Humulin R U-500 in 78 healthy volunteers is the regulatory route to a lower-priced alternative; approval would further widen access without changing the molecule. ## Conclusion Humulin R is the original manufactured copy of human insulin: fast enough to cover a meal, gone within a working day, and priced far below the engineered versions that replaced it. In people who cannot produce insulin, it does the job the body cannot, and long-running research shows that good blood sugar control with this generation of insulin protects eyes, nerves and kidneys. In hospital settings it remains the reference treatment for dangerously high potassium and for the acid crisis that follows total insulin failure. Against newer versions, the measurable differences in average blood sugar are small; the differences in low-blood-sugar episodes are real but modest and largest in type 1 diabetes. The costs are equally concrete. Low blood sugar is the defining hazard and is linked to later cognitive decline. Weight gain is expected. Injection sites thicken if they are not rotated. Whether decades of injected insulin accelerate biological aging is unresolved, and that question matters more to a longevity-minded adult than any point of average blood sugar. The evidence base is uneven. Much of the head-to-head comparison was funded by companies that sell both the old and the new products, the professional bodies whose guidance favors the newer versions receive substantial industry support, and insurers have a financial reason to prefer the cheaper option. Neither type has been followed long enough to compare deaths or organ damage. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**